Is NUS a good stock to buy right now?

Based on our 6-factor quantitative model, NU SKIN ENTERPRISES, INC. (NUS) receives a "Reduce" rating with a composite score of 45.2/100. It is ranked #2,280 out of 4,446 stocks. Key factor scores: Quality 50/100, Value 79/100, Momentum 31/100. The timing signal is "Neutral". This is quantitative analysis only — not investment advice.

What is the stock rating for NUS?

NU SKIN ENTERPRISES, INC. (NUS) has a "Reduce" rating and 2-star score. The composite score of 45.2 ranks it #2,280 among 4,446 U.S. stocks. Ratings are updated weekly using academically-proven factor models.

What sector is NUS in?

NU SKIN ENTERPRISES, INC. operates in the Consumer Staples sector (Wholesale industry) with a market cap of $354 million. It is classified as a small-cap stock.

Does NUS pay a dividend?

Yes, NUS pays a dividend with a current yield of 1.97%. The Consumer Staples sector average yield is 0.38%. For every $1,000 invested, you would receive approximately $19.70 in annual dividend income.

What is NUS's P/E ratio?

NUS has a trailing P/E ratio of 2.33x. The Consumer Staples sector average is 33.1x. This below-average P/E may indicate the stock is undervalued.

How profitable is NUS?

NUS's quality factor score is 50/100. Gross margin: 69.3%. ROE: 19.1% vs sector average 7.7%. High margins suggest pricing power and competitive moats.

How is NUS valued compared to peers?

NUS's value factor score is 79/100 (higher = cheaper). Key multiples: P/E 2.3x, EV/EBITDA 5.9x. The stock appears attractively valued versus peers.

What is NUS's debt level?

NUS's debt-to-equity ratio is 75%. Sector average: 72%. Moderate leverage is normal for established companies.

NUS has a beta of 1.00, meaning it tracks the market. Stability score: 50/100.

Does NUS have high short interest?

NUS's short interest factor score is 18/100 (higher = less short selling). Elevated short interest may indicate bearish sentiment or short squeeze potential.

NUS Stock Analysis: Top Small-Cap Reduce (Score 45.2/100) | Blank Capital Research

Data Series	1D	5D	1M	YTD	1Y	3Y	5Y	10Y
NUS	-1.44%	+1.48%	+2.04%	-21.83%	+23.89%	-	-	-
Industry Proxy XLP	-1.29%	+0.59%	-3.91%	+6.04%	+3.81%	-	-	-
U.S. Market SPY	-0.07%	+3.60%	+0.34%	-0.36%	+29.52%	-	-	-
Alpha vs Market	-1.38%	-2.12%	+1.70%	-21.47%	-5.64%	-	-	-
Alpha vs Sector	-0.15%	+0.90%	+5.94%	-27.87%	+20.08%	-	-	-

Metric	NUS	Benchmark
P/E Ratio	2.3x	-93%
EV/EBITDA	5.9x	-15%
Price / Book	0.5x

Stock Entity	Score▼	Quality	Value	Momentum	P/E Ratio	ROE	Gross Margin	Net Margin	Rev Growth	D/E Ratio	Market Cap	Compare
ITRN Ituran Location & Control Ltd.	60	48	82	70	19.6x	122.1%	47.8%	16.8%	-	0.0x	$1.0B	VS
SENEA Seneca Foods Corp	55	49	59	69	10.3x	14.4%	14.3%	6.7%	70.9%	39.0x	$1.1B	VS
JBSS SANFILIPPO JOHN B & SON INC	54	50	57	61	12.8x	20.2%	19.3%	6.3%	14.0%	11.0x	$965M	VS
ARW ARROW ELECTRONICS, INC.	53	50	73	63	15.8x	7.2%	11.2%	1.6%	11.9%	337.0x	$7.5B	VS
SFD SMITHFIELD FOODS INC	53	50	72	57	13.8x	11.9%	19.9%	7.5%	7.3%	29.0x	$11.3B	VS
BG Bunge Global SA	53	50	54	69	24.9x	5.7%	5.4%	1.8%	67.3%	59.0x	$24.8B	VS
DAR DARLING INGREDIENTS INC.	53	50	55	71	142.7x	1.5%	24.1%	1.2%	13.3%	114.0x	$9.9B	VS
ADM Archer-Daniels-Midland Co	52	50	52	64	54.6x	2.8%	6.4%	0.8%	-8.4%	33.0x	$34.9B	VS
CTVA Corteva, Inc.	52	49	51	60	50.6x	4.7%	42.9%	0.2%	-57.2%	76.0x	$56.3B	VS
MO ALTRIA GROUP, INC.	51	50	67	51	13.6x	-	62.1%	33.8%	-2.2%	-990.0x	$109.5B	VS
NUS NU SKIN ENTERPRISES, INC.	45	50	79	31	2.3x	19.1%	69.3%	10.4%	-17.1%	75.0x	$354M

Key Ratio	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016
Gross Margin %	0.7%	0.7%	0.7%	0.7%	0.7%	0.7%	0.7%	0.8%	0.8%	0.8%	0.8%
Operating Margin %	0.0%	0.0%	-0.1%	0.0%	0.0%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%
EBITDA Margin %	0.0%	0.0%	-0.1%	0.0%	0.0%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%
Net Margin %	0.1%	0.1%	-0.1%	0.0%	0.0%	0.1%	0.1%	0.1%	0.0%	0.1%	0.1%
FCF Margin %	9.7%	-	-	-	-	-	12.2%	4.6%	4.9%	10.6%	10.2%
ROE %	0.2%	0.2%	-0.2%	0.0%	0.1%	0.2%	0.2%	0.2%	0.2%	0.2%	0.2%
ROA %	0.1%	0.1%	-0.1%	0.0%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%
ROIC %	6.1%	6.5%	-18.4%	4.6%	9.8%	20.3%	24.6%	23.4%	23.1%	32.5%	25.2%

Key Ratio

TTM

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

Gross Margin %

0.7%

0.8%

Operating Margin %

0.0%

-0.1%

0.0%

0.1%

EBITDA Margin %

0.0%

-0.1%

0.0%

0.1%

Net Margin %

0.1%

-0.1%

0.0%

0.1%

0.0%

0.1%

FCF Margin %

9.7%

12.2%

4.6%

4.9%

10.6%

10.2%

ROE %

0.2%

-0.2%

0.0%

0.1%

0.2%

ROA %

0.1%

-0.1%

0.0%

0.1%

ROIC %

6.1%

6.5%

-18.4%

4.6%

9.8%

20.3%

24.6%

23.4%

23.1%

32.5%

25.2%

Line Item	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
	$1.5B	$1.5B	$1.7B	$2.0B	$2.2B	$2.7B	$2.6B	$2.4B	$2.7B	$2.3B	$2.2B	$2.2B
	—	$454M	$550M	$612M	$631M	$675M	—	—	—	—	—	—
	$1.1B	$1.0B	$1.2B	$1.4B	$1.6B	$2.0B	$1.9B	$1.8B	$2.0B	$1.8B	$1.7B	$1.8B
Gross Margin	69.3%	69.5%	68.2%	68.9%	71.7%	75.0%	74.5%	76.0%	76.3%	78.0%	77.3%	78.2%
	—	$11M	$13M	$23M	$23M	$27M	—	—	—	—	—	—
Depreciation	—	—	—	—	—	—	$74M	$77M	$83M	$72M	$72M	$71M
Total Operating Expenses	—	$966M	$1.3B	$1.3B	$1.5B	$1.8B	—	—	—	—	—	—
	$61M	$66M	-$152M	$48M	$111M	$234M	$258M	$267M	$241M	$274M	$231M	$245M
EBIT	$61M	$66M	-$152M	$48M	$111M	$234M	$258M	$267M	$241M	$274M	$231M	$245M
EBITDA	$61M	$66M	-$152M	$48M	$111M	$234M	$330M	$332M	$303M	$337M	$285M	$283M
Operating Margin	3.9%	4.4%	-8.8%	2.5%	5.0%	8.7%	10.0%	11.1%	9.0%	12.0%	10.5%	10.9%
EBITDA Margin	3.9%	4.4%	-8.8%	2.5%	5.0%	8.7%	12.8%	13.7%	11.3%	14.8%	12.9%	12.6%
	—	—	—	$26M	$14M	$11M	—	—	—	—	—	—
	—	$196M	-$175M	$27M	$89M	$232M	—	—	—	—	—	—
Income Tax Expense	—	$36M	-$28M	$18M	-$16M	$85M	$65M	$82M	$98M	$136M	$70M	$79M
	$154M	$160M	-$147M	$9M	$105M	$147M	$191M	$174M	$122M	$129M	$143M	$133M
Net Margin	10.4%	10.8%	-8.5%	0.4%	4.7%	5.5%	7.4%	7.2%	4.5%	5.7%	6.5%	5.9%
	$3.25	$3.25	$-2.95	$0.17	$2.10	$2.93	$3.66	$3.13	$2.21	$2.45	$2.58	$2.29
Diluted EPS	$3.25	$3.18	$-2.95	$0.17	$2.07	$2.86	$3.66	$3.13	$2.21	$2.45	$2.58	$2.29
Weighted Avg Basic	—	49M	50M	50M	50M	50M	—	—	—	—	—	—
Weighted Avg Diluted	—	50M	50M	50M	51M	51M	—	—	—	—	—	—

Line Item

TTM

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

$1.5B

$1.7B

$2.0B

$2.2B

$2.7B

$2.6B

$2.4B

$2.7B

$2.3B

$2.2B

—

$454M

$550M

$612M

$631M

$675M

—

$1.1B

$1.0B

$1.2B

$1.4B

$1.6B

$2.0B

$1.9B

$1.8B

$2.0B

$1.8B

$1.7B

$1.8B

Gross Margin

69.3%

69.5%

68.2%

68.9%

71.7%

75.0%

74.5%

76.0%

76.3%

78.0%

77.3%

78.2%

—

$11M

$13M

$23M

$27M

—

Depreciation

—

$74M

$77M

$83M

$72M

$71M

Total Operating Expenses

—

$966M

$1.3B

$1.5B

$1.8B

—

$61M

$66M

-$152M

$48M

$111M

$234M

$258M

$267M

$241M

$274M

$231M

$245M

EBIT

$61M

$66M

-$152M

$48M

$111M

$234M

$258M

$267M

$241M

$274M

$231M

$245M

EBITDA

$61M

$66M

-$152M

$48M

$111M

$234M

$330M

$332M

$303M

$337M

$285M

$283M

Operating Margin

3.9%

4.4%

-8.8%

2.5%

5.0%

8.7%

10.0%

11.1%

9.0%

12.0%

10.5%

10.9%

EBITDA Margin

3.9%

4.4%

-8.8%

2.5%

5.0%

8.7%

12.8%

13.7%

11.3%

14.8%

12.9%

12.6%

—

$26M

$14M

$11M

—

$196M

-$175M

$27M

$89M

$232M

—

Income Tax Expense

—

$36M

-$28M

$18M

-$16M

$85M

$65M

$82M

$98M

$136M

$70M

$79M

$154M

$160M

-$147M

$9M

$105M

$147M

$191M

$174M

$122M

$129M

$143M

$133M

Net Margin

10.4%

10.8%

-8.5%

0.4%

4.7%

5.5%

7.4%

7.2%

4.5%

5.7%

6.5%

5.9%

$3.25

$-2.95

$0.17

$2.10

$2.93

$3.66

$3.13

$2.21

$2.45

$2.58

$2.29

Diluted EPS

$3.25

$3.18

$-2.95

$0.17

$2.07

$2.86

$3.66

$3.13

$2.21

$2.45

$2.58

$2.29

Weighted Avg Basic

—

49M

50M

—

Weighted Avg Diluted

—

50M

51M

—

NU SKIN ENTERPRISES, INC. (NUS) Stock Analysis — April 2026 Rating, Price, and Forecast

Last updated: April 2026

Company Overview — What Does NU SKIN ENTERPRISES, INC. Do?

Nu Skin Enterprises, Inc. develops and distributes beauty and wellness products worldwide. It provides skin care systems, including ageLOC Spa systems, ageLOC Transformation anti-aging skin care systems, and ageLOC LumiSpa skin treatment and cleansing devices; and ageLOC Boost, as well as a range of other cosmetic and personal care products. The company also offers ageLOC Youth nutritional supplements, ageLOC TR90 weight management and body shaping systems, LifePak nutritional supplements, ageLOC Meta nutritional supplements, and Beauty Focus Collagen+ skin care supplements, as well as other weight management products. In addition, it is involved in the research and product development of skin care products and nutritional supplements. Further, the company operates retail stores and service centers in Mainland China. It sells its products under the Nu Skin, Pharmanex, and ageLOC brands. The company promotes and sells its products directly, as well as through distributors and Website. Nu Skin Enterprises, Inc. was founded in 1984 and is headquartered in Provo, Utah. NU SKIN ENTERPRISES, INC. (NUS) is classified as a small-cap stock in the Consumer Staples sector, specifically within the Wholesale industry. The company is led by CEO Ryan S. Napierski and employs approximately 13,400 people, headquartered in Wilmington, Utah. With a market capitalization of $354M, NUS is one of the notable companies in the Consumer Staples sector.

NU SKIN ENTERPRISES, INC. (NUS) Stock Rating — Reduce (April 2026)

As of April 2026, NU SKIN ENTERPRISES, INC. receives a Reduce rating with a composite score of 45.2/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.NUS ranks #2,280 out of 4,446 stocks in our coverage universe. Within the Consumer Staples sector, NU SKIN ENTERPRISES, INC. ranks #89 of 180 stocks, placing it in the upper half of its Consumer Staples peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

NUS Stock Price and 52-Week Range

NU SKIN ENTERPRISES, INC. (NUS) currently trades at $7.52. The stock lost $0.11 (1.4%) in the most recent trading session. The 52-week high for NUS is $14.62, which means the stock is currently trading -48.6% from its annual peak. The 52-week low is $5.32, putting the stock 41.4% above its annual trough. Recent trading volume was 467K shares, suggesting relatively thin trading activity.

Is NUS Overvalued or Undervalued? — Valuation Analysis

NU SKIN ENTERPRISES, INC. (NUS) carries a value factor score of 79/100 in the Blank Capital model, suggesting the stock trades at a meaningful discount to its fundamental earning power. The trailing price-to-earnings ratio is 2.33x, compared to the Consumer Staples sector average of 33.11x — a discount of 93%. The price-to-book ratio stands at 0.45x, versus the sector average of 1.74x. The price-to-sales ratio is 0.23x, compared to 0.35x for the average Consumer Staples stock. On an enterprise value basis, NUS trades at 5.90x EV/EBITDA, versus 6.93x for the sector.

Based on these multiples, NU SKIN ENTERPRISES, INC. appears attractively valued relative to both its sector peers and the broader market. Value-oriented investors may find the current entry point compelling, particularly if the company's fundamental quality metrics also score well.

NU SKIN ENTERPRISES, INC. Profitability — ROE, Margins, and Quality Score

NU SKIN ENTERPRISES, INC. (NUS) earns a quality factor score of 50/100, indicating solid business quality with consistent operational execution. The return on equity (ROE) is 19.1%, compared to the Consumer Staples sector average of 7.7%, which is within a healthy range. Return on assets (ROA) comes in at 11.0% versus the sector average of 3.1%.

On a margin basis, NU SKIN ENTERPRISES, INC. reports gross margins of 69.3%, compared to 26.2% for the sector. The operating margin is 3.9% (sector: 2.9%). Net profit margin stands at 10.4%, versus 1.6% for the average Consumer Staples stock. Revenue growth is running at -17.1% on a trailing basis, compared to 3.1% for the sector. The overall profitability profile is adequate, though there may be room for margin expansion.

NUS Debt, Balance Sheet, and Financial Health

NU SKIN ENTERPRISES, INC. has a debt-to-equity ratio of 75.0%, compared to the Consumer Staples sector average of 72.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 2.08x, indicating strong short-term liquidity. Total debt on the balance sheet is $229M. Cash and equivalents stand at $252M.

NUS has a beta of 1.00, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for NU SKIN ENTERPRISES, INC. is 50/100, reflecting average volatility within the normal range for its sector.

NU SKIN ENTERPRISES, INC. Revenue and Earnings History — Quarterly Trend

In TTM 2026, NU SKIN ENTERPRISES, INC. reported revenue of $1.54B and earnings per share (EPS) of $3.25. Net income for the quarter was $154M. Gross margin was 69.3%. Operating income came in at $61M.

In FY 2025, NU SKIN ENTERPRISES, INC. reported revenue of $1.49B and earnings per share (EPS) of $3.25. Net income for the quarter was $160M. Gross margin was 69.5%. Revenue grew -14.3% year-over-year compared to FY 2024. Operating income came in at $66M.

In Q3 2025, NU SKIN ENTERPRISES, INC. reported revenue of $364M and earnings per share (EPS) of $0.35. Net income for the quarter was $17M. Gross margin was 70.5%. Revenue grew -15.3% year-over-year compared to Q3 2024. Operating income came in at $22M.

In Q2 2025, NU SKIN ENTERPRISES, INC. reported revenue of $386M and earnings per share (EPS) of $0.43. Net income for the quarter was $21M. Gross margin was 68.8%. Revenue grew -12.1% year-over-year compared to Q2 2024. Operating income came in at $31M.

Over the past 8 quarters, NU SKIN ENTERPRISES, INC. has demonstrated a growth trajectory, with revenue expanding from $439M to $1.54B. Investors analyzing NUS stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

NUS Dividend Yield and Income Analysis

NU SKIN ENTERPRISES, INC. (NUS) currently pays a dividend yield of 2.0%. At this yield, a $10,000 investment in NUS stock would generate approximately $$197.00 in annual dividend income. This compares to the Consumer Staples sector average dividend yield of 0.4%, meaning NUS offers above-average income for its sector. The net margin of 10.4% provides reasonable coverage for the dividend, though investors should monitor payout sustainability.

NUS Momentum and Technical Analysis Profile

NU SKIN ENTERPRISES, INC. (NUS) has a momentum factor score of 31/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 37/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 18/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

NUS vs Competitors — Consumer Staples Sector Ranking and Peer Comparison

Within the Consumer Staples sector, NU SKIN ENTERPRISES, INC. (NUS) ranks #89 out of 180 stocks based on the Blank Capital composite score. This places NUS in the upper half of all Consumer Staples stocks in our coverage universe. Key competitors and sector peers include Ituran Location & Control Ltd. (ITRN) with a score of 60.3/100, DARLING INGREDIENTS INC. (DAR) with a score of 52.9/100, Bunge Global SA (BG) with a score of 53.0/100, SANFILIPPO JOHN B & SON INC (JBSS) with a score of 54.1/100, and Archer-Daniels-Midland Co (ADM) with a score of 52.2/100.

Comparing NUS against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full NUS vs S&P 500 (SPY) comparison to assess how NU SKIN ENTERPRISES, INC. stacks up against the broader market across all factor dimensions.

NUS Next Earnings Date

No upcoming earnings date has been announced for NU SKIN ENTERPRISES, INC. (NUS) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy NUS? — Investment Thesis Summary

The quantitative profile for NU SKIN ENTERPRISES, INC. suggests caution. The value score of 79/100 suggests attractive pricing relative to fundamentals. Momentum is weak at 31/100, a headwind for near-term performance.

In summary, NU SKIN ENTERPRISES, INC. (NUS) earns a Reduce rating with a composite score of 45.2/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on NUS stock.

Related Resources for NUS Investors

Explore more research and tools: NUS vs S&P 500 comparison, top Consumer Staples stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare NUS head-to-head with peers: NUS vs ITRN, NUS vs DAR, NUS vs BG.

Business quality

Valuation edge

Market alpha

Unlock Investment Thesis

Unlock Performance & Technicals

Unlock Valuation Tools

Institutional peer matrix

Dispersion: efficiency vs. valuation

Lateral intelligence network

Unlock Financial Statements

Unlock Ownership & Management

Intelligence Feed

Most CFOs Lift US Economic Outlook Despite War in Iran, Tariffs

Nu Skin Names Lantz Interim CFO

Nu Skin Names Clark Chief Operating Officer

Nu Skin Launches Prysm iO™: A Revolutionary AI-Powered Platform for Personalized Nutritional Wellness

Nu Skin Enterprises Appoints Chelsea Lantz as Interim Chief Financial Officer

Unlock Earnings Transcripts

Institutional Intelligence FAQ

Related Research & Tools

Related Consumer Staples Stocks

NU SKIN ENTERPRISES, INC. (NUS) Stock Analysis — April 2026 Rating, Price, and Forecast

Company Overview — What Does NU SKIN ENTERPRISES, INC. Do?

NU SKIN ENTERPRISES, INC. (NUS) Stock Rating — Reduce (April 2026)

NUS Stock Price and 52-Week Range

Is NUS Overvalued or Undervalued? — Valuation Analysis

NU SKIN ENTERPRISES, INC. Profitability — ROE, Margins, and Quality Score

NUS Debt, Balance Sheet, and Financial Health

NU SKIN ENTERPRISES, INC. Revenue and Earnings History — Quarterly Trend

NUS Dividend Yield and Income Analysis

NUS Momentum and Technical Analysis Profile

NUS vs Competitors — Consumer Staples Sector Ranking and Peer Comparison

NUS Next Earnings Date

Should You Buy NUS? — Investment Thesis Summary

Related Resources for NUS Investors

Comments

Institutional Benchmarks

Related research

Get alerted on rating changes

Intelligence Feed

Most CFOs Lift US Economic Outlook Despite War in Iran, Tariffs

Nu Skin Names Lantz Interim CFO

Nu Skin Names Clark Chief Operating Officer

Nu Skin Launches Prysm iO™: A Revolutionary AI-Powered Platform for Personalized Nutritional Wellness

Nu Skin Enterprises Appoints Chelsea Lantz as Interim Chief Financial Officer